OTCMKTS:PHGUF Pharming Group (PHGUF) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free PHGUF Stock Alerts $0.95 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.95▼$0.9550-Day Range$0.95▼$1.2052-Week Range$0.95▼$1.40VolumeN/AAverage Volume115 shsMarket Capitalization$619.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Pharming Group alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Pharming Group Stock (OTCMKTS:PHGUF)Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Read More PHGUF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHGUF Stock News HeadlinesApril 23, 2024 | americanbankingnews.comPharming Group (OTCMKTS:PHGUF) Sets New 1-Year Low at $0.95April 19, 2024 | finance.yahoo.comPharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025April 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 18, 2024 | finance.yahoo.comPharming Group announces the placement of €100 million convertible bonds due 2029April 8, 2024 | markets.businessinsider.comOptimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market ExpansionApril 8, 2024 | finanznachrichten.dePharming Group N.V.: Pharming announces completion of enrollment in pediatric clinical trial of leniolisibApril 4, 2024 | finance.yahoo.comPharming Group announces the 2024 Annual General Meeting of ShareholdersApril 3, 2024 | finance.yahoo.comPharming Group to participate in April investor conferencesApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 17, 2024 | finance.yahoo.comPharming Group N.V. (AMS:PHARM) Analysts Are Pretty Bullish On The Stock After Recent ResultsMarch 16, 2024 | finance.yahoo.comPharming Group Full Year 2023 Earnings: US$0.015 loss per share (vs US$0.021 profit in FY 2022)March 15, 2024 | markets.businessinsider.comPharming Group’s Strong Financial Performance and Growth Potential Merit Buy RatingFebruary 29, 2024 | finance.yahoo.comPharming Group to report fourth quarter and full year 2023 financial results on March 14February 20, 2024 | uk.investing.comPharming Group NV (PHAR)January 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Pharming Group (OtherPHGUF)January 8, 2024 | finanznachrichten.dePharming Group N.V.: Pharming Group announces updated full year 2023 guidance and Joenja U.S. launch updateJanuary 8, 2024 | markets.businessinsider.comPharming Group Projects 2023 Total Revenues To Rise 19%January 8, 2024 | finance.yahoo.comPharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateNovember 21, 2023 | finance.yahoo.comPharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibNovember 10, 2023 | finance.yahoo.comPharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalNovember 7, 2023 | finance.yahoo.comPharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific MeetingOctober 26, 2023 | msn.comPharming GAAP EPS of $0.01 beats by $0.005, revenue of $66.7M beats by $4.87MOctober 12, 2023 | finanznachrichten.dePharming Group N.V.: Pharming Group to report third quarter 2023 financial results on October 26October 12, 2023 | finance.yahoo.comPharming Group to report third quarter 2023 financial results on October 26September 22, 2023 | finance.yahoo.comPharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?September 9, 2023 | msn.comPharming Group: Pipeline Progresses With APDS Phase 3 InitiationAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Pharming Group (PHAR)See More Headlines Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2015Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CUSIPN/A CIKN/A Webwww.pharming.com Phone(171) 524-7400Fax31-0-71-524-7445Employees332Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,550,000.00 Net Margins-4.11% Pretax Margin-4.90% Return on Equity-4.47% Return on Assets-2.12% Debt Debt-to-Equity Ratio0.76 Current Ratio4.06 Quick Ratio3.33 Sales & Book Value Annual Sales$245.32 million Price / Sales2.53 Cash Flow$0.01 per share Price / Cash Flow94.77 Book Value$0.34 per share Price / Book2.79Miscellaneous Outstanding Shares652,410,000Free FloatN/AMarket Cap$619.79 million OptionableNot Optionable Beta1.07 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Sijmen de Vries M.B.A. (Age 65)M.D., President, CEO & Executive Director Comp: $1.18MMr. Jeroen Wakkerman (Age 55)Chief Financial Officer Ms. Mireille Sanders M.Sc. (Age 56)Chief Operations Officer Susanne EmbletonInvestor Relations ManagerMr. Ruud Van Outersterp (Age 60)Chief Ethics & Compliance Officer Dr. Anurag Relan M.D. (Age 52)MPH, Chief Medical Officer Mr. Stephen Toor (Age 53)Chief Commercial Officer & GM Americas Dr. Alexander Breidenbach M.B.A.Chief Business OfficerDr. Bruno M. L. Giannetti (Age 72)Consultant More ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELWave Life SciencesNASDAQ:WVESIGA TechnologiesNASDAQ:SIGAZymeworksNYSE:ZYMEPraxis Precision MedicinesNASDAQ:PRAXView All Competitors PHGUF Stock Analysis - Frequently Asked Questions How have PHGUF shares performed in 2024? Pharming Group's stock was trading at $1.1750 at the beginning of 2024. Since then, PHGUF stock has decreased by 19.1% and is now trading at $0.95. View the best growth stocks for 2024 here. How were Pharming Group's earnings last quarter? Pharming Group (OTCMKTS:PHGUF) announced its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative net margin of 4.11% and a negative trailing twelve-month return on equity of 4.47%. How do I buy shares of Pharming Group? Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PHGUF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
